Filing Flows › Humacyte (HUMA) › Q3 2025
Humacyte (HUMA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Humacyte (HUMA) reported revenue of $753K for the third quarter 2025 (Q3 2025) and +150% from the quarter before.
Humacyte, Q3 2025: revenue $753K, net loss $17.5M, operating cash flow −$23.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $753K | +150% | — |
| Operating profit | −$24.4M | — | — |
| Net earnings | −$17.5M | — | — |
| Operating cash flow | −$23.9M | — | — |
What changed
Revenue was $753K in Q3 2025, up 150% from the previous quarter. Symvess was the largest line at 93% of revenue.
Operating costs exceeded revenue by $24.4M, an operating margin of -3239.0%. The quarter ended with a net loss of $17.5M, narrower than the previous quarter's $37.7M loss. Non-operating items added $6.9M, -39% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$23.9M. Non-cash charges added back $1.3M of depreciation and $2.5M of share-based compensation. Working capital and other items used $10.2M. Capital expenditures of $49K exceeded it, leaving free cash flow of −$24.0M.
Questions
What was Humacyte's revenue in the third quarter 2025?
Humacyte (HUMA) reported revenue of $753K for the third quarter 2025 (Q3 2025) and +150% from the quarter before.
Source: Humacyte 10-Q on SEC EDGAR.